Chair, Department of Otolaryngology/Head and Neck Surgery
Thomas J. Dark Distinguished Professor of Otolaryngology/Head and Neck Surgery

Specialty: 

Head and neck surgery, cancer cell biology.

Contact Information:

  • Appointment Scheduler: (984) 974-0000
  • Surgery Scheduler: Patricia Longest (919) 966-7491
  • Executive Assistant: Dawn Wilson (919) 843-7091

Education:

  • MD: University of North Carolina School of Medicine, 1985-1989
  • Internship: Department of General Surgery, University of North Carolina Hospitals, 1989-1990
  • Residency: Department of Otolaryngology/Head and Neck Surgery, University of North Carolina Hospitals, 1990-1994
  • Fellowship: Surgical Oncology, Department of Surgery, University of North Carolina Hospitals, 1994-1996
  • MMHC: Vanderbilt Owen Graduate School of Management, 2009-2010
  • A. Privatim, Honorary Master of Arts, Yale University, 2017

Professional Experience:

  • Chair, Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill School of Medicine, 2018-present
  • Thomas J. Dark Distinguished Professor of Otolaryngology/Head and Neck Surgery, 2018-present
  • Professor: Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill School of Medicine, 2018-present
  • Professor: Department of Pathology, Yale School of Medicine, 2013-2018
  • Section Chief: Section of Otolaryngology, Department of Surgery, Yale School of Medicine, 2012-2018
  • Professor, Otolaryngology: Department of Surgery, Yale School of Medicine, 2012-2018
  • Director: Head and Neck Disease Center, Smilow Cancer Hospital, 2012-2018
  • Co-Director: Virus and Other Infection-associated Cancers (VOIC) Program, Yale Cancer Center, 2012-2018
  • Professor with Tenure: Department of Otolaryngology, Vanderbilt University, 2012-2012
  • Barry and Amy Baker Chair in Laryngeal, Head and Neck Research, Vanderbilt University, 2012-2012
  • Co-leader, Thoracic and Head & Neck Program, Vanderbilt Ingram Cancer Center, 2009-2012
  • Adjunct Associate Professor Surgery, Meharry Medical College, 2008-2012
  • Ingram Professor of Cancer Research, Vanderbilt Ingram Cancer Center, Vanderbilt University, 2006-2012
  • Associate Professor with Tenure, Otolaryngology, Vanderbilt University, 2003-2012
  • Associate Professor with Tenure, Cancer Biology, Vanderbilt University, 2003-2012
  • Director, Barry Baker Laboratory of Head and Neck Oncology, Department of Otolaryngology, Vanderbilt University, 2003-2012
  • Chief Otolaryngology, VA Medical Center, 2003-2004
  • Co-director, Otolaryngology/Head and Neck Resident Curriculum, University of North Carolina at Chapel Hill, 2002-2003
  • Assistant Professor, Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, 2001-2001
  • Associate Professor with Tenure, Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, 2001-2003
  • Associate Professor with Tenure, Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, 2001-2003
  • Associate Professor with Tenure, Biochemistry & Biophysics, University of North Carolina at Chapel Hill, 2001-2003
  • Assistant Professor, Biochemistry & Biophysics, University of North Carolina at Chapel Hill, 2000-2001
  • Assistant Professor, Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, 1996-2001

Honors:

  • 2016-2018 “America’s Top Doctors for Cancer,” Executive List, Castle Connolly
  • 2009-2018 “America’s Top Doctors,” Editions 8-14, Castle Connolly
  • 2005-2018 “America’s Top Doctors for Cancer,” Editions, Castle Connolly
  • 2015 “Top Doctors for Cancer,” Newsweek Magazine
  • 2014 Presidential Citation, AHNS, American Head and Neck Society
  • 2014 “America’s Top Doctors – New York Metro Area,” Edition 17, Castle Connolly
  • 2011 5-star Patient Satisfaction Awards for Overall Quality of Doctor Care
  • Given for achieving overall quality of care in the 90th-99th percentile
  • Professional Research Consultants (PRC) in Omaha, NE
  • 2010 “America’s Top Physicians”, Consumers’ Research Council of America & SLD Industries, Inc.
  • 2004 Distinguished Service Award in Scientific Programs, Exhibits, Continuing Education Courses and Instructional Course, American Academy of Otolaryngology-Head and Neck Surgery Foundation
  • 2002 Harris P. Mosher Award, Recognizing excellence in clinical research, The American Laryngological, Rhinological and Otological Society
  • 2000 Jefferson Pilot Fellowship, Recognizing the outstanding Assistant Professor in the School of Medicine
  • 1994 The American Laryngological, Rhinological, and Otological Society, Inc., Resident Research Award, 1st prize
  • 1994 Nathan A. Womack Scholar, Recognizing the outstanding surgical resident
  • 1991- 1992 Newton D. Fischer Society Temporal Bone Dissection Award
  • 1989 Michiko Kuno Award for Best Presentation of John B. Graham, Student Research Society
  • 1989 Graduated with Honors and Distinction, University of North Carolina School of Medicine
  • 1989 Deborah C. Leary Award, For the outstanding medical student research paper
  • 1988 Alpha Omega Alpha
  • 1986-1989 Academic Honors, Medical School
  • 1985 Phi Lambda Upsilon (Honorary Chemical Society)
  • 1985 Student Research & Recognition Foundation Award, Recognition for outstanding Senior Student Majoring in Chemistry
  • 1985 Graduated with Honors in Chemistry
  • 1981-1985 John Motley Morehead Scholarship
  • 1984 Phi Beta Kappa
  • 1982 Phi Eta Sigma (Freshman Honor Society)

Recent Publications:

  • Cheraghlou S, Kuo P, Otremba MD, Mehra S, Yarbrough WG,Judson BL. Extracapsular extension is not a significant prognostic indicator in non-squamous cancers of the major salivary glands. Cancers of the Head and Neck, 2018. Published July 3, 2018.
  • Li H, Torabi SJ, G. Yarbrough, Mehra S, Osborn HA, Judson B. Association of human papillomavirus status at head and neck carcinoma subsites with overall survival. JAMA Otolaryngol Head Neck Surg. Published online May 10, 2018. doi:10.1001/jamaoto.2018.0395
  • Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, G. Yarbrough, Burtness BA, Judson BL. Adjuvant therapy in major salivary gland cancers: an analysis of 8580 patients in the National Cancer Database. Head and Neck. May 2018. doi: 10.1002/hed.24984. [Epub ahead of print]
  • Cheraghlou S, Kuo P, Mehra S, Yarbrough WG, Judson BL. Untreated oral cavity cancer: Long-term survival and factors associated with treatment refusal. Laryngoscope. March 2018. doi: 10.1002/lary.26809.
  • Morse E, Henderson C, Mehra S, Carafeno, T, Judson BL, Sasaki CT, Yarbrough WG, Longley P, Chan E. A Clinical Care Pathway to Reduce ICU Usage in Head and Neck Microvascular Reconstruction. Otolaryngology-Head and Neck Surgery, 2018.PMID: 30060705 DOI: 10.1177/0194599818782404
  • Cheraghlou S, Kuo P, Mehra S, Agogo, G, Bhatia A, Husain ZA, Yarbrough WG,Burtness, BA, Judson BL. Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database. Head and Neck, 2018. PMID: 29756412 DOI: 10.1002/hed.24984.
  • Zhang J, Chen T, Yang X, Cheng H, Späth SS, Clavijo PE, Chen J, Silvin C, Issaeva N, Su X, Yarbrough WG, Annunziata CM, Chen Z, Van Waes C. Attenuated TRAF3 fosters alternative activation of NF-κB and reduced expression of anti-viral interferon, TP53, and RB to promote HPV-positive head and neck cancers. Cancer Research, 2018. PMID: 29921694 DOI: 10.1158/0008-5472.CAN-17-0642
  • Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer. Clinical Cancer Research, December 2017. 23(23):7276-7287. doi: 10.1158/1078-0432.CCR-17-1438
  • Cheraghlou S, Yu PK, Otremba MD, Park HS, Bhatia A, Zogg CK, Mehra S, Yarbrough WG, Judson BL. Treatment deintensification in human papillomavirus-positive oropharynx cancer: Outcomes from the National Cancer Data Base. Cancer. December 2017. doi: 10.1002/cncr.31104.
  • Cheraghlou S, Kuo P, Mehra S, Yarbrough WG, Judson BL. Salvage Surgery after Radiation Failure in T1/T2 Larynx Cancer: Outcomes following Total versus Conservation Surgery. Otolaryngology Head Neck Surgery. December 2017. 194599817742596. doi: 10.1177/0194599817742596.
  • Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA. Response. Journal of National Cancer Institute. November 2017. doi: 10.1093/jnci/djx230.
  • Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA. Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival. Journal of National Cancer Institute, October 2017. 109(10). doi: 10.1093/jnci/djx042.
  • Issaeva N, Burtness B, Yarbrough WG. TRAF3 and CYLD Gene Defects in HPV-Associated Head and Neck Cancer: Biomarker of Response and Indicator of Targets for New Therapies. Journal of Cancer Clinical Trials. October 2017. J Cancer Clin Trials 3: 1000142.
  • Fujiwara RJT, Burtness B, Husain ZA, Judson BL, Bhatia A, Sasaki CT, Yarbrough WG, Mehra S. Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment. Oral Oncology, August 2017. 71:129-137. doi: 10.1016/j.oraloncology.2017.06.013
  • Panaccione A, Zhang Y, Ryan M, Moskaluk CA, Anderson KS, Yarbrough WG*, Ivanov SV. MYB fusions and CD markers as tools for authentication and purification of cancer stem cells from salivary adenoid cystic carcinoma. Stem Cell Research, May 2017, 21:160-166.
  • Wamsley JJ, Gary C, Biktasova A, Hajek M, Bellinger G, Virk R, Issaeva N, Yarbrough WG*. Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner. Oncogenesis, April 2017, 6(4): e314.
  • Fujiwara RJ, Judson BL, Yarbrough WG, Husain Z, Mehra S. Treatment delays in oral cavity squamous cell carcinoma and association with survival. Head Neck, April 2017, 39(4):639-646.
  • Panaccione, Y. Zhang, Y. Mi, Y. Mitani, G. Yan, M.L. Prasad, W.H. McDonald, A.K. El-Naggar, W.G. Yarbrough*, S.V. Ivanov. Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma. Oral Oncology, March 2017, 66:38-45.
  • Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, Mills GB, Grandis JR. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. JCI Insight, March 2017,2(6): e90449.
  • Wamsley J. J., C. Gary, A. Biktasova, M. Hajek, G. Bellinger, R. Virk, N. Issaeva, and G. Yarbrough*. Loss of LZAP Inactivates p53 and Regulates Sensitivity of Cells to DNA Damage in a p53-dependent Manner. Oncogenesis, February 2017, 6(4):e314.
  • Lee N.C., J.R Kelly., H.S. Park, G. Yarbrough, B.A. Burtness, and Z.A. Husain. The risk of level IB nodal involvement in oropharynx cancer: guidance for submandibular gland sparing irradiation. Practical Radiation Oncology, February 2017, pii: S1879-8500(17)30047-4.
  • Morse E, Judson BL, Husain ZA, Burtness B, Yarbrough WG,Sasaki CT,Cheraghlou S,Mehra S. Treatment Delays in Primarily Resected Oropharyngeal Squamous Cell Carcinoma: National Benchmarks and Survival Associations.Otolaryngology-Head and Neck Surgery, 2018. PMID: 30060700 DOI: 10.1177/0194599818779052
  • Wamsley J., N. Issaeva, H. An, X. Lu, L. Donehower & G. Yarbrough*. LZAP is a novel Wip1 binding partner and positive regulator of its phosphatase activity in vitro. Cell Cycle, 2017 Jan 17; 16(2):213-223.
  • R. Kelly, H.S. Park, Y. An, J.N. Contessa, W.G. Yarbrough, B. A. Burtness, R. Decker, Z. Husain. Comparison of Survival Outcomes Among Human Papillomavirus–Negative cT1-2 N1-2b Patients with Oropharyngeal Squamous Cell Cancer Treated with Upfront Surgery vs Definitive Chemoradiation Therapy. JAMA Oncology,January 2017. doi:10.1001/jamaoncol.2016.5769.
  • Tan, L. Song, M. Graham, A. Schettino, D. Navaratnam, W.G. Yarbrough, J. Santos-Sacchi, and A.V., Ivanova. Novel role of the mitochondrial protein Fus1 in protection from premature hearing loss via regulation of oxidative stress and nutrient and energy sensing. Antioxidants & Redox Signaling. January 2017. doi:10.1089/ars.2016.6851.
  • Panaccione, Y. Guo, W.G. Yarbrough, S.V. Ivanov. Expression Profiling of Clinical Specimens Supports the Existence of Neural Progenitor-Like Stem Cells in Basal Breast Cancers. Clinical Breast Cancer, January 2017, (4):298-306.e7.
  • Hajek, A. Sewell, S. Kaech, B. Burtness, W.G. Yarbrough*,N. Issaeva. TRAF3/CYLD Mutations Identify a Distinct Subset of Human Papilloma Virus-Associated Head and Neck Squamous Cell Carcinoma. Cancer, January 2017, 123(10):1778-1790.
  • An, Y., Park, H., Kelly, J.,Stahl, J.,G. Yarbrough,Burtness, B.A., Contessa, J., Decker, R., Koshy, M., Husain, Z.A. The Prognostic Value of Extranodal Extension in Human Papilloma Virus-associated Oropharyngeal Squamous Cell Carcinoma. Cancer2017, 123(14):2762-2772.
  • Fujiwara, RJT, Husain ZA, Burtness BA, Judson BL, Bhatia A, Sasaki CT, Yarbrough WG, Mehra S. Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: primary surgical resection vs. nonsurgical treatment. Oral Oncology, 2017, 71:129-137.
  • Husain ZA, Chen T, Corso CD, Wang Z, Park H, Judson B, Yarbrough WG, Deshpande H, Mehra S, Kuo P, Decker RH, Burtness BA. A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma. JAMA Oncol, 2017, 3(3):358-365.
  • Brandt, S., Simonik, E.A., Cai, Y., Kimmelshue, K.N., Brantley, D., Loomans, H.A., Andl, C., Westlake, G., Youngblood, V.M., Chen, J., G. Yarbrough, Brown, B.T. LIM-Only Protein 4 (LMO4) and LIM Domain Binding Protein 1 (LDB1) Promote Growth and Metastasis of Human Head and Neck Cancer (LMO4 and LDB1 in Head and Neck Cancer)PLOS One, 2016 Oct 25, 11(10): e0164804.
  • Yarbrough, W.G., A.Panaccione, M.T. Chang, S. Ivanov. Clinical and Molecular Insights Into Adenoid Cystic Carcinoma: Neural Crest-Like Stemness as a Target. Laryngoscope Investigative Otolaryngology; 60-77, August 2016.
  • Kuo, P., Sosa, J.A., Burtness, B.A., Husain, Z.A., Mehra, S., Roman, S.A.,G. Yarbrough, Judson, B.L. Treatment Trends and Survival Effects of Chemotherapy for Hypopharyngeal cancer: Analysis of the National Cancer database. Cancer 2016, 122(12):1853-60.
  • Panaccione A., M.T. Chang, B.E. Carbone, Y. Guo, C.A. Moskaluk, R.K. Virk, L. Chiriboga, M.L. Prasad, B. Judson, S. Mehra, G. Yarbrough*,S.V. Ivanov. NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem-Like Cells in Adenoid Cystic Carcinoma. Clinical Cancer Research 2016, 22(8):2083-95.
  • Gary, C., Hajek, M., Biktasova, A., Bellinger, G., G. Yarbrough, Issaeva, N. Selective Antitumor Activity of Roscovitine in Head and Neck Cancer. Oncotarget 2016,7(25):38598-38611.
  • Schwam Z.G., Burtness B,Yarbrough G., Mehra S., Husain Z., Judson B.L.National treatment patterns in patients presenting with Stage IVC head and neck cancer: analysis of the National Cancer Database. Cancer Med.2015, Dec;4(12):1828-35.
  • Uzhachenko, R., A. Shanker, G. Yarbroughand A.V. Ivanova. Mitochondria, calcium, and tumor suppressor Fus1: At the crossroad of cancer, inflammation and autoimmunity, Oncotarget,2015,6(25):20754-72.
  • Baldassarri, R., R. Aronberg, A.W. Levi, G. Yarbrough,D. Kowalski, and D. Chhieng. Detection and genotype of high-risk human papillomavirus in fine-needle aspirates of patients with metastatic squamous cell carcinoma is helpful in determining tumor origin. American Journal of Clinical Pathology2015, 143(5):694-700.
  • Comprehensive Genome Atlas Network.Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature2015, 517(7536):576-82.
  • Yazlovitskaya E.M., Voziyan P.A., Manavalan T., Yarbrough W.G. and Ivanova A.V.Cellular oxidative stress response mediates radiosensitivity in Fus1-deficient mice. Cell Death and Disease 2015, 6:e1652.
  • Farmer R.W., L. McCall, F. J. Civantos, J.N. Myers, G.Yarbrough,B. Murphy, M. O’Leary, R. Zitsch, and B.A. Siegel. Lymphatic Drainage Patterns in Oral Squamous Cell Carcinoma: Findings of the ACOSOG Z0360 (Alliance) Study. Otolaryngology–Head and Neck Surgery2015, 152(4):673-7.
  • Aronberg, R.M., S.R. Punekar, S.I. Adam, B.J. Judson, S. Mehra, and G. Yarbrough*.Esophageal perforation caused by edible foreign bodies: a systematic review of the literature. Laryngoscope 2015, 125(2):371-8.
  • Parfenov, M., C.S. Pedamallu, N. Gehlenborg, S.S. Freeman, L. Danilova, C.A. Bristow CA, S. Lee, A.G. Hadjipanayis, E.V. Ivanova, M.D. Wilkerson, A. Protopopov, L. Yang, S. Seth, X. Song, J. Tang, X. Ren, J. Zhang, A. Pantazi, N. Santoso, A.W.Xu, H. Mahadeshwar, D.A.Wheeler, R.I. Haddad, J. Jung, A.I. Ojesina, N. Issaeva,G. Yarbrough, D.N. Hayes, J.R. Grandis, A.K. El-Naggar, M. Meyerson, P.J. Park, L. Chin, J.G. Seidman, P.S. Hammerman, and R. Kucherlapati. Cancer Genome Atlas Network. Characterization of HPV and host genome interactions in primary head and neck cancers. Proceedings of the National Academy of Sciences 2014, 111(43):15544-9.
  • Kuo, P., M.M. Chen, R.H. Decker, G. Yarbrough,and B.L. Judson. Hypopharyngeal cancer incidence, treatment, and survival: temporal trends in the United States. Laryngoscope 2014, 124(9):2064-9.
  • Moser, R., C. Xu, M. Kao, J. Annis, L.A. Lerma, C.M. Schaupp, K.E. Gurley, I.S. Jang, A. Biktasova, G. Yarbrough, A.A. Margolin, C. Grandori, C.J. Kemp, and E. Méndez. Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clinical Cancer Research. 2014, 20(16):4274-88.
  • Chen, M.M., S.A. Roman, G. Yarbrough, B.A. Burtness, J.A. Sosa, B.J. Judson. Trends and variations in the use of adjuvant therapy for patients with head and neck cancer. Cancer2014, 120(21):3353-60.
  • Thompson, P.D., A. Sakwe, R. Koumangoye, G. Yarbrough,J. Ochieng, and D.R. Marshall DR. Alpha-2 Heremans Schmid. Glycoprotein (AHSG) modulates signaling pathways in head and neck squamous cell carcinoma cell line SQ20B. Experimental Cell Research 2014, 321(2):123-32.
  • Uzhachenko, R., S.V. Ivanov, G. Yarbrough,A. Shanker, R. Medzhitov, and A.V. Ivanova. Fus1/Tusc2 is a novel regulator of mitochondrial calcium handling, Ca2+-coupled mitochondrial processes, and Ca2+-dependent NFAT and NF-κB pathways in CD4+ T cells. Antioxidants and Redox Signaling 2014, 20(10):1533-47.
  • Sewell, A., B. Brown, A. Biktasova, G.B. Mills, Y. Lu, D.R. Tyson, N. Issaeva, and G.Yarbrough*. Reverse Phase Protein Array Profiling of Oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. Clinical Cancer Research2014, 20(9):2300-11.
  • Luryi, A.L., G.Yarbrough, L.M. Niccolai, S. Roser, S.G. Reed, C.A. Nathan, M.G. Moore, T. Day, and B.L. Judson. Public Awareness of Head and Neck Cancers: A Cross-Sectional Survey, Journal of the American Medical Association Otolaryngology-Head & Neck Surgery 2014, 140(7):639-46.
  • Yarbrough, W.G.*, Sewell, E. Tickle, E. Rhinehardt, R. Harkleroad, M. Bennett, D. Johnson, L. Wen, M. Pfeiffer, M. Benegas, and J. Morath. A Tool to determine financial impact of adverse events in healthcare: Healthcare Quality Calculator.Journal of Patient Safety2014, 10(4):202-10.
  • Ivanov, S.V., A. Panaccione, D. Nonaka, M.L. Prasad, K.L. Boyd, B. Brown, Y. Guo, A. Sewell, and G.Yarbrough*. Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. British Journal of Cancer2013, 109(2):444-51.
  • Godoy, J.M., A. Sewell, B. Johnston, B.T. Brown, X. Lu, R.J. Sinard, S. Rohde, K. Mannion, J.L. Netterville, and G. Yarbrough*.Viable biobanking of primary head and neck squamous cell carcinoma.Laryngoscope2013, 123(3):641-5.
  • Athavale, S.M., S. Rangarajan, L. Dharamsi, S. Wentz, S. Phillips, T. McRackan, and G. Yarbrough*.AlloDerm and DermaMatrix implants for parotidectomy reconstruction: a histologic study in the rat model. Head & Neck2013, 35(2):242-9.
  • Slebos, R., N. Jehmlich, B. Brown, Z. Yin, C. Chung, G.Yarbrough, and D. Liebler. Proteomic Analysis of Oropharyngeal Carcinomas Reveals Novel HPV-Associated Biological Pathways. International Journal of Cancer2013, 132(3):568-79.
  • Ivanov, S.V., A. Panaccione, A. Brown, Y. Guo, C.A. Moskaluk, M.J. Wick, J.L. Brown, A.V. Ivanova, N. Issaeva, A.K. El-Naggar, and G.Yarbrough*.TRKC Signaling is Activated in Adenoid Cystic Carcinoma and Requires NT-3 to Stimulate Invasive Behavior. Oncogene2013, 32(32):3698-710.
  • Yazlovitskaya, E.M., R. Uzhachenko, P.A. Voziyan, G. Yarbroughand A.V. Ivanova. A novel radioprotective function for the mitochondrial tumor suppressor protein Fus1. Cell Death and Disease2013, 4:e687
  • Bennett, M., J.M. Morath, G. Yarbrough, R. Sinard, J. Netterville, and R.D. Eavey. The Mortality Observed-to-Expected Ratio in Otolaryngology. Otolaryngology Head and Neck Surgery2013, 148(1):59-63.
  • Lu, X., H An., R. Jin, M. Zou, Y. Guo, P.F. Su, D. Liu, Y. Shyr, and G.Yarbrough*. PPM1A is a RelA phosphatase with tumor suppressor-like activity. Oncogene 2013, 33(22):2918-27.
  • Husain, H., A. Psyrri, A. Markovic, T. Rampias, E. Pectasides, H. Wang, R. Slebos, G.Yarbrough, B. Burtness, and C.H. Chung. Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. Laryngoscope2012, 22(12):2762-8.
  • Hoshino, D., J. Jourquin, S.W. Emmons, T. Miller, M. Goldgof, K. Costello, D.R. Tyson, B. Brown, Y. Lu, N.K. Prasad, B. Zhang, G.B. Mills, G.Yarbrough, V. Quaranta, M. Seiki, and A.M. Weaver. Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKCα invasive signaling axis. Science Signaling2012, 5(241):ra66.
  • Vlacich, G., R. Diaz, S.W. Thorpe, B.A. Murphy, W. Kirby, R.J. Sinard, B. Shakhtour, Y. Shyr, P. Murphy, J.L. Netterville, G.Yarbrough, A.J. Cmelak. Intensity-modulated radiation therapy with concurrent Carboplatin and Paclitaxel for locally advanced head and neck cancer: toxicities and efficacy. Oncologist2012, 17(5):673-81.
  • Gubanova, E., B. Brown, S.V. Ivanov, T. Helleday, G.B. Mills, G.Yarbrough, N. Issaeva. Downregulation of SMG-1 in HPV-Positive Head and Neck Squamous Cell Carcinoma Due to Promoter Hypermethylation Correlates with Improved Survival. Clinical Cancer Research2012, 18(5):1257-1267.
  • Gilbert, J., B. Murphy, M.S. Dietrich, E. Henry, R. Jordan, A. Counsell, P. Wirth, G.Yarbrough, R.J. Slebos, and C.H. Chung. Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer. Cancer2012, 118(4):1007-13.
  • Athavale, S.M., S. Phillips, B. Mangus, J. Datta, R.J. Sinard, J.L. Netterville, B.B. Burkey, and G. Yarbrough*. Complications of alloderm and dermamatrix for parotidectomy reconstruction. Head & Neck2012, 34(1):88-93.
  • Zimmerman, L.J., M. Li, G.Yarbrough, R.Slebos, and D.C. Liebler. Global stability of plasma proteomes for mass spectrometry-based analyses. Molecular & Cellular Proteomics2012, 1(6):M111.
  • Liu, D., W.D. Wang, D.B. Melville, Y.I. Cha, Z. Yin, N. Issaeva, E.W. Knapik, and G.Yarbrough.Tumor suppressor Lzap regulates cell cycle progression, doming and zebrafish epiboly. Developmental Dynamics2011, 240(6):1613-25.
  • An, H., X. Lu, D. Liu, and G.Yarbrough*.LZAP inhibits p38 MAPK (p38) phosphorylation and activity by facilitating p38 association with the wild-type p53 induced phosphatase 1 (WIP1). PLoS One2011, 6(1):e16427.
  • Hatakeyama, H., H. Cheng, P. Wirth, A. Counsell, S.R. Marcrom, C.B. Wood, P.R. Pohlmann, J. Gilbert, B. Murphy, G. Yarbrough, D.L. Wheeler, P.M. Harari, Y. Guo, Y. Shyr, R.J. Slebos, and C.H. Chung. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. Public Library of Science One2010, 5(9):e12702.
  • Li, M., W. Gray, H. Zhang, C.H. Chung, D. Billheimer, G. Yarbrough, D.C. Liebler, Y. Shyr, and R.J. Slebos. Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling. Journal of Proteome Research2010, 9(8):4295-305.
  • Diaz, R., J.J. Jaboin, M. Morales-Paliza, E. Koehler, J.G. Phillips, S. Stinson, J. Gilbert, C.H. Chung, B.A. Murphy, G.Yarbrough, P.B. Murphy, Y. Shyr, and A.J. Cmelak. Hypothyroidism as a Consequence of Intensity-Modulated Radiotherapy with Concurrent Taxane-Based Chemotherapy for Locally Advanced Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics 2010, 77(2):468-76.
  • Hartert, T.V., K. Carroll, T. Gebretsadik, G. Yarbrough,K. Woodward, and P. Minton. Vanderbilt Center for Asthma and Environmental Health Research Investigators and Collaborators. The Tennessee Children’s Respiratory Initiative: Objectives, design and recruitment results of a prospective cohort study investigating infant viral respiratory illness and the development of asthma and allergic diseases. Respirology2010, 15:691-699.
  • Chung, C.H., J. Aulino, N.J. Muldowney, H. Hatakeyama, J. Baumann, B. Burkey, J. Netterville, R. Sinard, G.Yarbrough, A.J. Cmelak, R.J. Slebos, Y. Shyr, J. Parker, J. Gilbert, and B.A. Murphy. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Annals of Oncology 2010 21(4):864-70.
  • Civantos, F.J., R.P. Zitsch, D.E. Schuller, A. Agrawal, R.B. Smith, R. Nason, G. Petruzelli, C.G. Gourin, R.J. Wong, R.L. Ferris, A. El Naggar, J.A. Ridge, and R.C. Paniello, K. Owzar, L. McCall, D.B. Chepeha, G. Yarbrough, and J.N. Myers. Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. Journal of Clinical Oncology2010, 28(8):1395-400.
  • Murphy, B.A., M.S. Dietrich, N. Wells, K. Dwyer, S.H. Ridner, H.J. Silver, J. Gilbert, C.H. Chung, A. Cmelak, B. Burkey, G.Yarbrough, R. Sinard, and J. Netterville. Reliability and Validity of the Vanderbilt Head and Neck Symptom Survey: A Tool to Assess Symptom Burden in Patients Treated with Chemoradiation. Head & Neck2010, 32(1): 26-37.
  • Law, J.H., A.S. Whigham, P.S. Wirth, D. Liu, M.Q. Pham, S. Vadivelu, K.C. Kirkbride, B.T. Brown, B.B. Burkey, R.J. Sinard, J.L. Netterville, and G.Yarbrough*. Human-in-mouse modeling of primary head and neck squamous cell carcinoma. Laryngoscope 2009, 119(12):2315-23.
  • Yang, E.S., B.M. Murphy, C.H. Chung, J.L. Netterville, B.B. Burkey, J. Gilbert, W.G. Yarbrough, R. Sinard, and A.J. Cmelak. Evolution of clinical trials in head and neck cancer. Critical Reviews in Oncology/Hematology2009, 71(1):29-42.
  • Baumann, J.L., S. Cohen, A.N. Evjen, J.H. Law, S. Vadivelu, A. Attia, J.S. Schindler, C.H. Chung, P.S. Wirth, C.J. Meijer, P.J. Snijders, G. Yarbrough, and R.J. Slebos. Human papillomavirus in early laryngeal carcinoma.Laryngoscope2009, 119(8):1531-1537.
  • Clark, E.S., B. Brown, A.S. Whigham, A. Kochiashvili, G. Yarbrough, and A. Weaver. Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 11q13 amplicon. Oncogene2009, 28(3):431-44, 2009.
  • Mukherjee, K., M.P. Cash, B.B. Burkey, G. Yarbrough, J.L. Netterville, and W.V. Melvin. Antegrade and retrograde endoscopy for treatment of esophageal stricture. The American Journal of Surgery2008, 74(8):686-7.
  • Gilbert, J., A. Cmelak, Y. Shyr, J. Netterville, B.B. Burkey, R.J. Sinard, G.Yarbrough, C.H. Chung, J.M. Aulino, B.A. Murphy. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck. Cancer 2008, 113(1):186-92.
  • Slebos, R.J.C., M. Li, S. Vadivelu, B.B. Burkey, J.L. Netterville, R. Sinard, J. Gilbert, B. Murphy, C.H. Chung, and G. Yarbrough*.Microsatellite mutations in buccal cells are associated with aging and head and neck carcinoma. British Journal of Cancer2008, 98(3):619-26.
  • Yarbrough, W.G., A. Whigham, B. Brown, M. Roach, and R. Slebos. Phosphoinositide kinase-3 status is associated with the presence or absence of human papilloma virus in head and neck squamous cell carcinomas.International Journal of Radiation Oncology – Biology Physics 2007, 69(2 Suppl):S98-101.
  • Wang, J., H. An, M.W. Mayo, A.S. Baldwin, and G. Yarbrough*.LZAP, a putative tumor suppressor selectively inhibits NF-kB. Cancer Cell2007, 12(3):239-51.
  • Clark, E.S., A.S. Whigham, G.Yarbrough, and A.M. Weaver. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Research2007, 67(9):4227-35.
  • Slebos, R.J.C., M. Li, A.N. Evjen, J. Coffa, Y. Shyr, and G. Yarbrough*.Mutagenic effect of cadmium on tetranucleotide repeats in human cells. Mutation Research2006, 602(1-2):92-9.
  • Chung, C.H., K. Ely, L. McGavran, M. Varella-Garcia, J. Parker, N. Parker, C. Jarrett, J. Carter, B.A. Murphy, J.N. Netterville, B.B. Burkey, R. Sinard, A. Cmelak, S. Levy, G.Yarbrough, R.J. Slebos, and F.R. Hirsch. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. Journal of Clinical Oncology2006, 24(25): 4170-4176.
  • Chung, C.H., J.S. Parker, K. Ely, J. Carter, Y. Yi, B.A. Murphy, K.K. Ang, A. El-Naggar, A.M. Zanation, A.J. Cmelak, S. Levy, R.J. Slebos, and G. Yarbrough*. Gene expression profiles identify epithelial-to mesenchymal transition and activation of nuclear factor-kB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Research2006, 66(16): 8210-8218.
  • Stacy, D.R., K. Ely, P.P. Massion, G.Yarbrough, D.E. Hallahan, K.R. Sekhar, M.L. Freeman. Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head and Neck2006, 28: 813-818.
  • Whigham, A.S., J.L. Netterville, B.B. Burkey, R.J. Sinard, C.H. Chung, R.J.C. Slebos, and G. Yarbrough*.Short-term culture and in vivo modeling of primary head and neck squamous cell carcinoma. Archives of Otolaryngology – Head and Neck Surgery2006, 132(8): 901-02.
  • Yarbrough, W.G., R.J.C. Slebos, and D. Liebler. Proteomics: Clinical applications for head and neck squamous cell carcinoma. Head and Neck2006, 28(6): 549-558.
  • Chung, C.H. S. Levy, and G. Yarbrough*.Clinical application of genomics in head and neck cancer. Head and Neck2006, 28(4): 360-368.
  • Slebos, R.J.C., Y. Yi, K. Ely, J. Carter, A. Evjen, X. Zhang, Y. Shyr, B.M. Murphy, A.J. Cmelak, B.B. Burkey, J.L. Netterville, S. Levy, G. Yarbrough, and C.H. Chung. Gene expression differences associated with HPV status in head and neck squamous cell carcinoma. Clinical Cancer Research2006, 12:701-709.
  • Wang, J., X. He, Y. Luo, and G.Yarbrough*.A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2. Biochemical Journal2006, 393(2):489-501.
  • Brinson, G.M., B.A. Senior, and G.Yarbrough*.Endoscopic management of retained airgun projectiles in the paranasal sinuses. Otolaryngology-Head and Neck Surgery2004, 130(1):25-30.
  • Becker, M.T., C.G. Shores, K.K. Yu, and G. Yarbrough*. Molecular assay to detect metastatic head and neck squamous cell carcinoma. Archives of Otolaryngology – Head and NeckSurgery 2004, 130(1):21-7.
  • Zanation, A.M., X. Yin, C. Shores, and G. Yarbrough*.Phenotypic and microarray gene expression analysis of tri-dimensional raft modeled human head and neck squamous cell carcinoma. Otolaryngology-Head and Neck Surgery2004, 131(5):577-84.
  • Shores, C.G., X. Yin, W. Funkhouser, and G.Yarbrough*. Clinical evaluation of a new molecular method for detection of micrometastases in head and neck squamous cell carcinoma. Archives of Otolaryngology Head and Neck Surgery2004, 130:937-942.
  • Chung, C.H., J.S. Parker, G. Karaca, J. Wu, W.K. Funkhouser, D. Moore, D. Butterfoss, D. Xiang, A. Zanation, X. Yin, W.W. Shockley, M.C. Weissler, L.G. Dressler, C.G. Shores, G.Yarbrough, and C.M. Perou. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell2004, 5(5):489-500.
  • Yarbrough, W.G., Bessho, A. Zanation, J.E. Bisi, and Y. Xiong. Human Tumor Suppressor ARF Impedes S-phase Progression Independent of p53. Cancer Research 2002, 62(4):1171-7.
  • Yu, K.K., A.M. Zanation, J.R. Moss and G. Yarbrough*. Familial head and neck cancer: Molecular analysis of a new clinical entity. Laryngoscope2002, 112(9):1587-93.
  • Yarbrough, W.G*. The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma. Laryngoscope2002, 112(12):2114-28.
  • Mauser, A., E. Holley-Guthrie, A. Zanation, G.Yarbrough, W. Kaufmann, A. Klingelhutz, W.T. Seaman, and S. Kenney. The Epstein-Barr virus immediate-early protein BZLF1 induces expression of E2F-1 and other proteins involved in cell cycle progression in primary keratinocytes and gastric carcinoma cells. Journal of Virology2002, 76:12543-12552.
  • Ferguson, M., T.L. Smith, A.M. Zanation and G. Yarbrough*.Radiofrequency tissue volume reduction: multilesion vs single-lesion treatments for snoring. Archives of Otolaryngology-Head & Neck Surgery2001, 127(9):1113-8.
  • Poole, M.E., S.L. Sailer, J.G. Rosenman, J.E. Tepper, M.C. Weissler, W.W. Shockley, G. Yarbrough, H.C. Pillsbury III, M.J. Schell, and S.A. Bernard. Chemoradiation for Locally Advanced Squamous Cel Carcinoma of the Head and Neck for Organ Preservation and Palliation. Archives of Otolaryngology-Head & Neck Surgery2001, 127(12):1446-50.
  • Tschan, M.P., S. Vonlanthen, J.F. Cajot, U.R. Peters, E. Oppliger, D.C. Betticher, G. Yarbrough,M.F. Fey, and A. Tobler. Different p16INK4a and p14ARF expression patterns in acute myeloid leukaemia and normal blood leukocytes. Leukemia and Lymphoma 2001, 42(5):1077-87.
  • Labadie, R.F., G.Yarbrough, M.C. Weissler, H.C. Pillsbury, and S.K. Mukherji. Nodal volume reduction in head and neck squamous cell carcinoma after concurrent chemo- and radiotherapy: Correlation between CT and histopathologic findings. American Journal of Neuroradiology2000, 21(2):310-4.
  • Itoshima, T., T. Fujiwara, T. Waku, J. Shao, M. Kataoka, G. Yarbrough, T.J. Liu, J.A. Roth, N. Tanaka, and M. Kodama. Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F1 genes: Involvement of p53 ccumulation via ARF-mediated MDM2 down-regulation. Clinical Cancer Research2000, 6(7):2851-9.

Active Grants:

NIH/NIDCR – 5R01DE013173-15: Tumor suppressor qualities and mechanisms of LZAP activity: 12/1/2011 – 11/30/2018;
PI: Wendell Yarbrough
Direct costs per year: $250,000 Effort: 12%, 1.44 calendar

Completed Grants:

Yale Comprehensive Cancer Center – Cancer Center Support Grant Supplement: Molecular and Immunologic Profile of Head and Neck Squamous Cell Cancers Among HIV-Infected Individuals. 8/1/2016 – 8/31/2018;
PI: Wendell Yarbrough, Brinda Emu
Direct costs per year: $59,701 Effort: 5%

NIH/NCI – 5P30 CA016359-37: Yale Comprehensive Cancer Center:
8/1/2007 – 7/31/2017
PI: Schulman
Total costs for project period: $1,561,565 Effort: 5%
Plexxikon, Inc.: Role of TRKC in Salivary Adenoid Cystic Carcinoma:
10/01/2014-03/31/2015
PI: Wendell Yarbrough
Total costs for project period: $66,464 Effort: 1%

NIH/NIDCR – R21DE022641: Role of TrkC in Neurotropic Salivary Cancers:
09/01/2013-08/31/2015
P.I.: Sergey Ivanov, PhD. / (Co-Investigator) Wendell Yarbrough, MD
Direct costs per year:  $125,000 Percent effort: 3%
NCI/NIH – CCSG – P30CA016359: Head & Neck Squamous Cell Carcinoma Biospecimen and Clinical Data Acquisition: 09/01/2013-08/31/2014
PI: Wendell Yarbrough
Direct costs per year: $60,059 Effort: 1%

Yale Cancer Center – T-Tare: Divide and Conquer: Advancing Therapy for Head and Neck Squamous Cell Carcinoma:  07/01/2013-06/30/2014
P.I.: Wendell Yarbrough, MD
Direct costs per year:  $125,000 Percent effort: 10%, no salary

Yale Cancer Center – Pilot Project: GABA-regulated SOX10 Signaling as a Potential Therapeutic Target in Adenoid Cystic and Breast Basal-like Carcinomas:
06/01/2013-05/31/2014
P.I.: Wendell Yarbrough, MD
Direct costs per year:  $ 50,000 Percent effort: 2%, no salary

ACCRF Grant – Role of TrkC in Neurotropic Salivary Cancers The goal of the proposal is to explore the molecular mechanisms of TrkC and NT-3 involvement in ACC to assess efficacy of Trk inhibitors as a potential therapeutic strategy:
02/16/2013-02/15/2014
P.I.:  Wendell Yarbrough, MD
Direct costs per year:  $14,318 Percent effort: 1%

NIH/NIDCR – R21DE023228: Validated Modeling and Culture of Salivary Cancers the goal of this project is to create mouse xenograft models of human salivary cancers of multiple histologies:
12/01/2012-11/30/2014
P.I.:  Wendell Yarbrough, MD
Direct costs per year:  $137,500 Percent effort: 5%

NIH/NIDCR – R01DE013173:Tumor suppressor qualities and mechanisms of LZAP activity Determine LZAP tumor suppressor qualities and describe interactions with the p53-induced phosphatase, Wip1: 12/01/2012-11/30/2016
P.I.:  Wendell Yarbrough, MD
Direct costs per year:  $250,000   Percent effort:  16%

NIH/NIDCR Funded Extension, (CCSG) Cancer Center Support Grant- P30CA016359:The goal of this project is to support research and education to better facilitate the prevention, treatment and care of cancer related patients:
08/09/2007-07/31/2013
Role: Co-leader of Molecular Virology Program
P.I.:  Thomas Lynch, MD
Direct costs per year:  $2,900,000 Percent effort: 5%

NIH/NIDCR -R21DE018244: Cortactin in HNSCC Tumor Progression:
8/01/2007-7/31/2010
P.I.:  Alissa Weaver, PhD. – Principal Investigator, Wendell Yarbrough, MD – Co-Investigator
Total costs for project period:  $300,000.00
Percent effort: 5%

NCI – Comprehensive Minority Institution /Cancer Center Partnership (U54, PI, Harold   Moses) – U54CA163072: Pre-Pilot Project. Identification of serum biomarkers in HNSCC;
9/1/2006-8/31/2007
P.I.:  Wendell G. Yarbrough, M.D. and Sabina Francis M.D., Co-Principal Investigators
Total costs for project period:  $25,000
Percent effort: 5%, no salary

Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation Award: Biomarkers for HNSCC and Targets for Novel Therapies; 9/1/2006-8/31/2007
P.I.:  Wendell Yarbrough, MD
Total costs for project period:  $300,000
Percent effort: 5%, no salary

AAO-HNSF – Percy Memorial Research Award – American Academy of Otolaryngology-Head and Neck Surgery Foundation: Effect of PI3K inhibition in HPV-associated HNSCC
07/01/2006-06/30/2007
P.I.:  Wendell Yarbrough, MD
Project period:  $25,000.
Percent effort: 2%, no salary

THANC – Thyroid, Head and Neck Cancer Foundation, Senior Investigator Award-Head and Neck Cancer Research: Serum biomarkers for head & neck cancer;
7/1/2005 renewable yearly through 6/30/2009
P.I.:  Wendell Yarbrough, MD
Total costs for project period:  $50,000
Percent effort: 5%, no salary

NIH/NIDCR – R01DE013173: Novel protein regulator of tumor suppressor ARF & NF-kB;
5/1/2005-4/31/2010
P.I.:  Wendell Yarbrough, MD
Total costs for project period:  $1,250,000
Percent effort: 5%

Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation Award: Proteome Profiling of Human Serum
Project period:  7/1/2005-6/30/2006
P.I.:  Wendell Yarbrough, MD
Total costs for project period:  $50,000
Percent effort: 5%, no salary

ACOSOG – American College of Surgeons Oncology Group: A trial of lymphatic mapping and sentinel node lymphadenectomy for patients with T1 or T2 clinically N0 oral cavity squamous cell carcinoma
Project period:  1/1/2004 – 5/31/2006
P.I.:  Wendell Yarbrough, MD – Vanderbilt University. Institutional Principal
Percent effort: 3%, no salary

NIH/NCI-R21CA102161: Gene Expression as a Predictor of Metastasis in HNSCC
Project period:  7/01/2003-6/30/2005
P.I.:  Wendell Yarbrough, MD
Total costs for project period:  $200,000
Percent effort: 5%

ACOSOG – American College of Surgeons Oncology Group: A trial of lymphatic mapping and sentinel node lymphadenectomy for patients with T1 or T2 clinically N0 oral cavity squamous cell carcinoma
Project period:  2/1/2002 – 4/30/2003
P.I.:  Wendell Yarbrough, MD
Percent effort: 5%, no salary

Medical Alumni Endowment Research Grant:  Pre-clinical Studies of Tumor Suppressor ARF in Organotypic Raft Modeled Head and Neck Cancer
Project period: 6/1/2001-5/31/2002
P.I.:  Wendell Yarbrough, MD – Mentor. Adam M. Zanation
Total costs for project period:  $2,000
Percent effort: 2%, no salary

Alpha Omega Alpha Research Fellowship- Alpha Omega Alpha National Medical Honor Society:  ARF armed oncolytic viral therapy for head and neck cancer:  preclinical studies
Project period:  4/1/2001-4/1/2002
P.I.:  Wendell Yarbrough, MD – Adam M. Zanation, Recipient
Total costs for project period:  $3,500
Percent effort: 2%, no salary

Scott Neil Schwirck Fellowship – UNC School of Medicine:  Preclinical studies of ARF tumor suppressor therapy for head and neck cancer
Project period:  1/1/2001–1/01/2002
P.I.:  Wendell Yarbrough, MD
Total costs for project period:  $2,500
Percent effort: 2%, no salary

University Research Council – University of North Carolina: Development of a Smoking Prevention Video targeting middle school age children
Project period:  1/2000-12/2001
P.I.:  Wendell Yarbrough, MD, Carol G. Shores, M.D., Ph.D
Total costs for project period:  $10,000
Percent effort: 3%, no salary

University Research Council – University of North Carolina – Cancer Prevention Program:  A Controlled Study of the Effectiveness of a Smoking and Alcohol Prevention Video and Presentation Relating to Head and Neck Cancer in Middle School Students
Project period:  1/2000-12/2001
P.I.:  Wendell Yarbrough, MD, Adam M. Zanation, Carol G. Shores, M.D., Ph.D
Total costs for project period:  $4,000
Percent effort: 3%, no salary

National Institute of Dental and Craniofacial Research-R01DE013173:ARF as a therapeutic agent in oral malignancies.
Project period:  4/1/2000-3/31/2004
P.I.:  Wendell Yarbrough, MD
Total costs for project period:  $998,320
Percent effort: 2%

The American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc AAO-HNS Foundation Resident Research Grant: Cytokeratins as Molecular Markers for Head and Neck Cancer
Project period:  7/1/2000-6/30/2001
P.I.:  Wendell Yarbrough, MD – Mentor.  Marta K. Taylor, Recipient
Total costs for project period: $10,000
Percent effort: 2%, no salary

University Faculty Research Grant: Efficiency of Adenovirus Vector-mediated Gene Transfer to Oral Epithelial Cells is Correlated with Differentiation and Human Coxsackie and Adenovirus Receptor (hCAR) Expression
Project period:  12/1/1999-11/30/2001
P.I.:  Wendell Yarbrough, MD
Percent effort: N/A
Direct costs per year: N/A
Total costs for project period:  $620
Percent effort: 1%, no salary

Lineberger Comprehensive Cancer Center, Translational Research Award: p53-independent functions of ARF
Project period:  7/1/1999-6/30/2000
P.I.:  Wendell Yarbrough, MD
Total costs for project period:  $35,000
Percent effort: 10%, no salary

Medical Alumni Association – Medical Alumni Association Endowment Fund Grant: The tumor suppressive role of the CDK inhibitors p18 and p27 in ras-mediated epithelial carcinogenesis
Project period:  7/1/1999-6/30/2000
P.I.:  Wendell Yarbrough, MD – Mark E. Hutchin, Recipient
Total costs for project period:  $2,000
Percent effort: 2%, no salary

Triological Society – Triological Society Research Training Award: Adenoviral mediated ARF overexpression:  Effects on modeled human head and neck mucosa and squamous cell carcinoma
Project period:  7/1/1999-6/30/2000
P.I.:  Wendell Yarbrough, MD – Carol G. Shores, M.D., Ph.D., Recipient
Total costs for project period:  $25,000
Percent effort: 2%, no salary

Triological Society -Triological Society Research Training Award:  p16α and p16β expression in head and neck squamous cell carcinoma: Effects on proliferation and apoptosis.
Project period:  7/1/1997-6/30/1998
P.I.:  Wendell Yarbrough, MD – Rudolph Triana, M.D., Recipient
Total costs for project period:  $25,000
Percent effort: 2%, no salary

Lineberger Comprehensive Cancer Center – UNC Lineberger Comprehensive Cancer Center Clinical/Translational Research Award: Role of p16b in tumorigenesis.
Project period:  4/1/1997-3/31/1998
P.I.:  Wendell Yarbrough, MD
Total costs for project period:  $25,000
Percent effort: 5%, no salary

NIH/NCI -Lineberger Comprehensive Cancer Center – Supplemental Grant: Genetic predisposition to head and neck squamous cell carcinomas-Role of p16.
Project period:  9/30/1996-9/29/1997
P.I.:  Wendell Yarbrough, MD
Total costs for project period:  $105,202
Percent effort: 5%, no salary

NIH/NCI -K08CA072968:  p16 in head and neck squamous cell carcinogenesis
Project period:  3/1/1997-2/28/2002
P.I.:  Wendell Yarbrough, MD – Edison T. Liu, M.D., Sponsor
Total costs for project period:  $90,000
Percent effort: 5%

Academy Research Training Award – American Academy of Otolaryngology/Head and Neck Surgery: EMS1 amplification, expression and phosphorylation in head and neck squamous cell carcinomas
Project period:  7/1/1994-6/30/1995
P.I.:  Wendell Yarbrough, MD
Total costs for project period:  $15,000
Percent effort: 5%, no salary

Active Clinical Trials:  

Fox Chase Cancer Center-1407014279: Phase II trial of carboplatin/paclitaxel and cetuximab, followed by
carboplatin/paclitaxel/cetuximab and erlotinib, with correlative studies in patients with
metastatic or recurrent squamous cell carcinoma of the head and neck
P.I:   Barbara Burtness, MD
Direct costs per year: N/A
Project period: March 16, 2011-Current
Effort: 2%, no salary

Yale University Investigator Initiated Trial – 1404013771: Window study to assess the activity of demethylation therapy in patients with HPV positive compared with HPV negative HNSCC.
P.I: Wendell Yarbrough, MD & Hari Deshpande, MD
Direct costs per year: N/A
Project period: June 30, 1994-Current
Effort: 5%, no salary

Eastern Cooperative Oncology Group-1403013536: ECOG 3311: Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
P.I:   Benjamin Judson, MD
Role on project: Co-Investigator
Total costs for project period: N/A
Project period:  August 1, 2013-February 28, 2023
Percent effort: 1%, no salary

Completed Clinical Trials:

AbbVie (Abbott Pharmaceuticals) – Investigator initiated Pre-Clinical Study: PARP inhibition as a molecular therapeutic strategy to treat a subset of HNSCC:
P.I.: Wendell Yarbrough, MD
Direct costs per year:  $30,000
Project Period: : 08/01/2013-02/01/2014
Effort: 5%, no salary

NIH – Clinical Trial, Lead Site at University of Pittsburgh – Related to RC1 Grant: Comparison of biomarker modulation by inhibition of EGFR and/or src Family kinases using Erlotinib and Dasatinib in head and neck and lung cancers:
P.I.:  Jennifer Grandis, MD
Role on Project:  Institutional Principal Investigator, Vanderbilt University
Project Period-03/01/2010 to 03/01/2013
Percent effort: 5%, no salary

Onyx Pharmaceuticals: An open label, single arm study of intratumoral ONYX-015 plus
Intravenous cisplatin/5-FU inpatients with squamous cell carcinoma of the
head and neck (SCCHN) refractory to cisplatin/5 FU
P.I.:  Wendell Yarbrough, MD
Total costs for project period: N/A
Project period:  10/1/2002 – 2/28/2003
Percent effort: 5%, no salary

Doris Duke Clinical Research Fellowship: ONYX 015 intratumoral phase III clinical trial and preclinical studies of ARF armed oncolytic viral therapy for head and neck cancer
P.I.:  Wendell Yarbrough, MD – Mentor. Adam M. Zanation
Total costs for project period:  $25,000
Project period:  6/1/2001- 5/30/2002
Percent effort: 5%, no salary

Pfizer/ONYX Pharmaceuticals:  A randomized phase 3 trial of intratumoral injection of CI-1042 (ONYX015) plus intravenous cisplatin/5-fluorouracil versus intravenous cisplatin/5-fluorouracil alone in patients with recurrent squamous cell carcinoma of the head and neck (protocol 1042-001)
P.I.:  Wendell Yarbrough, MD
Total costs for project period: N/A
Project period:  11/1/2000 – 2/28/2003
Percent effort: 5%, no salary